Your browser doesn't support javascript.
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.
Dagan, Noa; Barda, Noam; Biron-Shental, Tal; Makov-Assif, Maya; Key, Calanit; Kohane, Isaac S; Hernán, Miguel A; Lipsitch, Marc; Hernandez-Diaz, Sonia; Reis, Ben Y; Balicer, Ran D.
  • Dagan N; Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.
  • Barda N; Software and Information Systems Engineering, Ben Gurion University, Be'er Sheva, Israel.
  • Biron-Shental T; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
  • Makov-Assif M; The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute, Boston, MA, USA.
  • Key C; Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.
  • Kohane IS; Software and Information Systems Engineering, Ben Gurion University, Be'er Sheva, Israel.
  • Hernán MA; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
  • Lipsitch M; The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute, Boston, MA, USA.
  • Hernandez-Diaz S; Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel.
  • Reis BY; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Balicer RD; Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.
Nat Med ; 27(10): 1693-1695, 2021 10.
Article in English | MEDLINE | ID: covidwho-1526092
ABSTRACT
To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89-100%) for any documented infection, 97% (91-100%) for infections with documented symptoms and 89% (43-100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Pregnancy Complications, Infectious / COVID-19 Vaccines / COVID-19 Subject: Pregnancy Complications, Infectious / COVID-19 Vaccines / COVID-19 Type of study: Etiology study / Incidence study / Observational study / Prognostic study / Risk factors Language: English Journal: Nat Med Clinical aspect: Etiology / Prognosis Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Pregnancy Complications, Infectious / COVID-19 Vaccines / COVID-19 Subject: Pregnancy Complications, Infectious / COVID-19 Vaccines / COVID-19 Type of study: Etiology study / Incidence study / Observational study / Prognostic study / Risk factors Language: English Journal: Nat Med Clinical aspect: Etiology / Prognosis Year: 2021
...